Traws Pharma, Inc. (TRAW)
(Delayed Data from NSDQ)
$0.42 USD
-0.01 (-2.30%)
Updated Jul 16, 2024 03:57 PM ET
After-Market: $0.43 +0.01 (2.38%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TRAW 0.42 -0.01(-2.30%)
Will TRAW be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TRAW based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRAW
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
TRAW: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TRAW
Traws Pharma Exec Resigns; Dispute Over Severance Pay
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
Traws Pharma announces poster on potency of COVID-19 candidate
Traws Pharma’s High-Stakes Merger: The Race Against Time for Financial Success
Onconova Therapeutics GAAP EPS of -$0.24 beats by $0.01, revenue of $0.06M in-line